Clay Siegall on the Cure of Hodgkin
Seattle Genetics was co- founded by Dr. Siegall in 1998. Serving as the President and Chief Executive Officer, Clay Siegall is also a board member of Seattle Genetics. Before he joined Seattle Genetics, Clay Siegall worked for Bristol-Myers Squibb Pharmaceuticals Research Institute between 1991 and 1997. Besides, Clay worked at the National Cancer Institute and National Institute of Health between 1988 and 1991. Clay Siegall is a board member of two private firms; Alder Biopharmaceuticals and Therapeutics. He attended the University of Maryland where he was honored with a Bachelor of Science in Zoology. Clay furthered his studies by pursuing a Ph.D. in Genetics from George Washington University.
Clay Siegell’s Influence to Seattle Genetics
Clay Siegall recently gave an opening speech in which at a keynote presentation at CHI’s 5th Annual Antibody-Drug Conjugates Conference in the summit. Addressing the attendees, Clay Siegall announced the pride of Seattle Genetics in introducing ADCETRIS, (brentuximab vedotin), a treatment that has been efficient in treating over 15,000 patients with lymphoma globally. Clay while addressing the conference said that the drug created a treatment opportunity for the foundation of therapy. The treatment program involves one of the most important near-long term milestones for lymphoma treatment. According to FDA and Biologics License Application (BLA) for ADCETRIS in the AETHERA setting of post-transplant series of therapy for Hodgkin Lymphoma, the patients have a higher risk of relapse.
Seattle Genetics is advancing seven clinical series of programs beyond ADCETRIS. The primary ADC programs include SGN-CD33A in acute leukemia and SGN-CD19A in non-Hodgkin lymphoma. The two generated hopeful results coupled with encouraging data leading to increased treatment programs. Seattle Genetics plans to report an increase in data related to treatment programs. Seattle works in close cooperation with various pharmaceutical and biotechnology companies to empower the production of more than 20 ADC’s in clinical development via collaboration and incorporation.
Asked where Seattle Genetics and ADC’s will be in approximately two years, Clay Siegall says that there are critical considerations in ADC’s generation including the internalizing of an antibody targeted on specific tumors. Since the inception of ADCETRIS in the industry, Seattle Genetics combines a series of elements for the successful formation of ADC’s.